Analytical performance evaluation of new DESI enhancements for targeted drug quantification in tissue sections
Desorption/ionization (DI)-mass spectrometric (MS) methods offer considerable advantages of rapidity and low-sample input for the analysis of solid biological matrices such as tissue sections. The concept of desorption electrospray ionization (DESI) offers the possibility to ionize compounds from so...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
1 June 2022
|
| In: |
Pharmaceuticals
Year: 2022, Volume: 15, Issue: 6, Pages: 1-18 |
| ISSN: | 1424-8247 |
| DOI: | 10.3390/ph15060694 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/ph15060694 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/1424-8247/15/6/694 |
| Author Notes: | Margaux Fresnais, Siwen Liang, Marius Breitkopf, Joshua Raoul Lindner, Emmanuelle Claude, Steven Pringle, Pavel A. Levkin, Konstantin Demir, Julia Benzel, Julia Sundheimer, Britta Statz, Kristian W. Pajtler, Stefan M. Pfister, Walter E. Haefeli, Jürgen Burhenne and Rémi Longuespée |
| Summary: | Desorption/ionization (DI)-mass spectrometric (MS) methods offer considerable advantages of rapidity and low-sample input for the analysis of solid biological matrices such as tissue sections. The concept of desorption electrospray ionization (DESI) offers the possibility to ionize compounds from solid surfaces at atmospheric pressure, without the addition of organic compounds to initiate desorption. However, severe drawbacks from former DESI hardware stability made the development of assays for drug quantification difficult. In the present study, the potential of new prototype source setups (High Performance DESI Sprayer and Heated Transfer Line) for the development of drug quantification assays in tissue sections was evaluated. It was demonstrated that following dedicated optimization, new DESI XS enhancements present promising options regarding targeted quantitative analyses. As a model compound for these developments, ulixertinib, an inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2 was used. |
|---|---|
| Item Description: | Gesehen am 24.08.2022 This article belongs to the special issue "Mass spectrometry imaging in pharmaceutical research" |
| Physical Description: | Online Resource |
| ISSN: | 1424-8247 |
| DOI: | 10.3390/ph15060694 |